arrow
T

Tao Peng

Science and Technology Innovation Center
H指数:38
被引数:6,914

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial

局部晚期肝细胞癌在阿替利珠单抗和贝伐珠单抗治疗后行肝切除术与维持治疗的比较(TALENTOP研究):一项多中心、开放标签、随机、III期临床试验

2026-08-200
PRE
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial

围手术期卡瑞利珠单抗联合瑞戈非尼 versus 手术单药治疗复发风险为中高危的可切除肝细胞癌患者(CARES-009):一项随机II/III期试验

2025-10-190
PRE
Sequential hepatectomy for hepatocellular carcinoma with inadequate future-liver-remnant after portal vein ligation in combination with apatinib plus camrelizumab (PLACES): a single-arm prospective pilot study
2025-02-010
OA
Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)
2024-12-310
OA